Lock Antibodies, Unlock Health
PrecisemAb is dedicated to developing conditionally active antibodies, providing patients with the safest and reassuring therapeutic options.
About PrecisemAb
Unlocking Precision in Antibody Therapy
Transforming Cancer Treatment Through Intelligent Antibody Design
PrecisemAb is redefining the future of biologics with its pioneering Antibody Lock Technology, designed to achieve tumor-selective precision while ensuring maximum safety.
Our mission is to reshape the future of antibody drugs through innovation, advancing global health and offering every patient a treatment option that is both effective and trustworthy.
Universal Antibody Lock
Our Universal Antibody Lock™ is a novel proprietary platform designed to generate conditionally active antibodies across multiple formats—including monoclonal, anti-drug, and bispecific antibodies. This technology not only enhances the selectivity but minimizes on-target toxicity, aiming to deliver safer and more effective therapeutic solutions for patients.
Antibody
Lock-Antibody
Normal Tissue
Inactivated
